

25 February 2016

CANNABIS LEGISLATION GIVES MMJ THE GREEN LIGHT

MMJ PhytoTech Limited (ASX:MMJ) (the "Company") is pleased to announce that the Turnbull Government's proposed medical cannabis legislation was successfully passed in parliament yesterday (24 February 2016). This news is a significant boost to MMJ's strategic entry into the Australian market as it has defined a legal pathway for the domestic cultivation, refinement and manufacturing of medical cannabis products for the first time.

Minister for Health, Sussan Ley, commented, "this is the missing piece in a patient's treatment journey and will now see seamless access to locally-produced medicinal cannabis products from farm to pharmacy."

MMJ PhytoTech's Managing Director, Andreas Gedeon, said "The introduction of this bill is timely in relation to the results of Phase 1 clinical trial undertaken by the Company, which have validated our commitment to the development of alternative delivery systems for medical cannabis."

"The introduction of MC legislation in Australia is indicative of the significant global regulatory momentum which is driving the demand for refined MC products and sophisticated delivery systems that provide patients with therapeutic benefits without the adverse impacts of smoking," said Mr Gedeon.

MMJ has long held the view that the future of regulated medical cannabis lies in alternative delivery systems, given the obvious contradiction of smoking a product prescribed for therapeutic purposes. The recent Phase 1 results, announced on 11 February, demonstrate that the Company's unique oral MC capsules are faster acting with a higher bioavailability than GW Pharmaceuticals' Sativex, without any significant side effects.

The capability of MMJ's vertically integrated "farm to pharma" operations in Canada, Israel and Europe position the Company at the forefront of an emerging industry. The establishment of our offshore operations has provided us with a head start and afforded us the technology, intellectual property and relationships necessary to move quickly in this newly regulated market. Whilst the Company intends to explore all options available to us, the Company's current intention is to pursue its planned importation of Satipharm CBD capsules for national distribution with an Australian partner, with the view to broadening our product offering in line with the new legislation.

The Company expects Phase 2 of the clinical Trial to commence in the second half of 2016.

For more information on the passing of this historic legislation, see the full media release at: [http://www.health.gov.au/internet/ministers/publishing.nsf/Content/667D4DBACBA53562CA257F63000D10DC/\\$File/SL013.pdf](http://www.health.gov.au/internet/ministers/publishing.nsf/Content/667D4DBACBA53562CA257F63000D10DC/$File/SL013.pdf)

For more information please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Gaelan Bloomfield
Manager, Marketing & PR
+61 431 303 567
gbloomfield@mmj.ca

ASX RELEASE

For media enquiries:

Whitney Fitzsimmons
Director Media & Communications
Market Eye
+61 448 285 646
Whitney.fitzsimmons@marketeye.com.au

About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. **Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.

<http://www.mmjphytech.com.au>